INTELLIA THERAPEUTICS, INC. Debt Securities, Available-for-sale, Amortized Cost
INTELLIA THERAPEUTICS, INC. (NTLA) had Debt Securities, Available-for-sale, Amortized Cost of $523.26 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $523.26M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $382.79M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $448.64M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $475.48M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $523.26M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $382.79M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $448.64M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $475.48M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $473.68M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $579.16M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $671.95M 10-K · filed 2026-02-26 |
| 2024-09-30 | $820.89M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $810.18M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $782.35M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $785.47M 10-K · filed 2025-02-27 |
| 2023-09-30 | $826.63M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $902.54M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $865.20M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $742.22M 10-K · filed 2024-02-22 |
| 2022-09-30 | $714.73M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $767.28M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $868.61M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $964.77M 10-K · filed 2023-02-23 |
| 2021-09-30 | $814.15M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $421.41M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $459.27M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $437.35M 10-K · filed 2022-02-24 |
| 2020-09-30 | $228.17M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $74.96M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $168.89M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $226.99M 10-K · filed 2021-02-26 |
| 2019-09-30 | $257.01M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $226.44M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $249.43M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $255.23M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |